The bispecific antibody therapeutics market is estimated to be worth USD 6.9 billion in 2030

AMERICAN CANYON, Calif. - July 23, 2020 - PRLog -- The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

§  A detailed assessment of the current market landscape of drug developers engaged in the development of bispecific antibody therapeutics.

§  A comprehensive analysis of novel technology platforms that are either currently available or being developed for the generation of bispecific antibody therapeutics.

§  Detailed profiles of marketed and clinical stage (phase II and phase III) bispecific antibody therapeutics.

§  Key takeaways from the bispecific antibody therapeutics pipeline.

§  An analysis of the initiatives of big biopharma players engaged in this domain.

§  An analysis of recent partnerships and collaboration agreements inked in bispecific antibody therapeutics domain.

§  A review on the key steps involved and challenges associated with the manufacturing of bispecific antibodies.

§  A clinical trial analysis of ongoing and planned studies related to bispecific antibody therapeutics.

§  A review of the key promotional strategies that have been adopted by the developers of the marketed bispecific antibodies.

§  A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

• Target Disease Indication

§  Autoimmune Disorders

§  Eye Disorders

§  Genetic Disorders

§  Hematological Malignancies

§  Infectious Diseases

§  Inflammatory Disorders

§  Skin Disorders

• Mechanism of Action

§  Cytokines Retargeting / Neutralization

§  Dual Ligands Blocking

• Antibody Format

§  Asymmetric

§  Martin Steiner (Chief Executive Officer, Synimmune)

§  Ludger Große-Hovest (Chief Scientific Officer, Synimmune)

§  Jane Dancer (Chief Business Officer, F-Star)

§  Siobhan Pomeroy (Senior Director, Business Development, Cytom X)

§  Yinjue Wang (Associate Director, Process Development, Innovent Biologics)

Key companies covered in the report (https://www.rootsanalysis.com/reports/view_document/bispe...)

§  Amgen

§  Ablynx

§  AbbVie

§  Affibody

§  Affimed

§  Alphamab

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html

Other Recent Offerings

1.      Global Preventive Vaccines Market, 2020-2030

2.      Endocannabinoid System Targeted Therapeutics Market, 2019-2030

3.      Antibody Contract Manufacturing Market, 2020-2030

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com